1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

When Expanded Access Also Means Off-Label Use, US FDA May Need New Policy

 
• By Derrick Gingery

For now, FDA is using a case-by-case approach for reviewing and approving expanded access applications asking for off-label uses.

FDA entrance sign 2016
FDA has encountered situations where an expanded access IND is necessary to allow an off-label use of an approved drug.

The US Food and Drug Administration's expanded access program now is receiving requests for off-label uses of approved drugs, creating a new policy question as the single-patient IND program likely is on the cusp of more growth.

Approved drugs do not require special FDA permission for an off-label use. In many cases, especially in oncology, off-label use...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

How Will Regulatory Filing Winds Blow Globally For Elevidys Following Patient Deaths?

 
• By Francesca Bruce

Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 
• By Eliza Slawther

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

More from Pathways & Standards